JP2013063968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013063968A5 JP2013063968A5 JP2012190429A JP2012190429A JP2013063968A5 JP 2013063968 A5 JP2013063968 A5 JP 2013063968A5 JP 2012190429 A JP2012190429 A JP 2012190429A JP 2012190429 A JP2012190429 A JP 2012190429A JP 2013063968 A5 JP2013063968 A5 JP 2013063968A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl group
- alkoxy
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 59
- 150000003839 salts Chemical class 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 20
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 19
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004434 sulfur atom Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 108091006277 SLC5A1 Proteins 0.000 claims 3
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 claims 1
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- YBMRCBYGWAPNMV-UJPKRVMBSA-N C[C@H]1C(C)C(C)(C)C[C@@H](C)NC2OC2NC(C)(C)C1 Chemical compound C[C@H]1C(C)C(C)(C)C[C@@H](C)NC2OC2NC(C)(C)C1 YBMRCBYGWAPNMV-UJPKRVMBSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012190429A JP6091811B2 (ja) | 2011-08-31 | 2012-08-30 | ピラゾール化合物及びその医薬用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011188121 | 2011-08-31 | ||
| JP2011188121 | 2011-08-31 | ||
| JP2012190429A JP6091811B2 (ja) | 2011-08-31 | 2012-08-30 | ピラゾール化合物及びその医薬用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017021326A Division JP2017082005A (ja) | 2011-08-31 | 2017-02-08 | ピラゾール化合物及びその医薬用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013063968A JP2013063968A (ja) | 2013-04-11 |
| JP2013063968A5 true JP2013063968A5 (enExample) | 2015-10-15 |
| JP6091811B2 JP6091811B2 (ja) | 2017-03-08 |
Family
ID=47756400
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012190429A Active JP6091811B2 (ja) | 2011-08-31 | 2012-08-30 | ピラゾール化合物及びその医薬用途 |
| JP2017021326A Ceased JP2017082005A (ja) | 2011-08-31 | 2017-02-08 | ピラゾール化合物及びその医薬用途 |
| JP2018088578A Ceased JP2018115216A (ja) | 2011-08-31 | 2018-05-02 | ピラゾール化合物及びその医薬用途 |
| JP2020081097A Ceased JP2020125348A (ja) | 2011-08-31 | 2020-05-01 | ピラゾール化合物及びその医薬用途 |
| JP2023075967A Ceased JP2023087032A (ja) | 2011-08-31 | 2023-05-02 | ピラゾール化合物及びその医薬用途 |
| JP2025000092A Withdrawn JP2025039641A (ja) | 2011-08-31 | 2025-01-06 | ピラゾール化合物及びその医薬用途 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017021326A Ceased JP2017082005A (ja) | 2011-08-31 | 2017-02-08 | ピラゾール化合物及びその医薬用途 |
| JP2018088578A Ceased JP2018115216A (ja) | 2011-08-31 | 2018-05-02 | ピラゾール化合物及びその医薬用途 |
| JP2020081097A Ceased JP2020125348A (ja) | 2011-08-31 | 2020-05-01 | ピラゾール化合物及びその医薬用途 |
| JP2023075967A Ceased JP2023087032A (ja) | 2011-08-31 | 2023-05-02 | ピラゾール化合物及びその医薬用途 |
| JP2025000092A Withdrawn JP2025039641A (ja) | 2011-08-31 | 2025-01-06 | ピラゾール化合物及びその医薬用途 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US8846746B2 (enExample) |
| EP (4) | EP3524599A1 (enExample) |
| JP (6) | JP6091811B2 (enExample) |
| KR (1) | KR101989203B1 (enExample) |
| CN (1) | CN103917535B (enExample) |
| AR (2) | AR087701A1 (enExample) |
| AU (1) | AU2012302723B2 (enExample) |
| BR (1) | BR112014004651B1 (enExample) |
| CA (1) | CA2845127C (enExample) |
| CL (1) | CL2014000490A1 (enExample) |
| CO (1) | CO6890098A2 (enExample) |
| CY (1) | CY1121631T1 (enExample) |
| DK (1) | DK3199533T3 (enExample) |
| HK (1) | HK1202290A1 (enExample) |
| IL (1) | IL230763A (enExample) |
| MX (1) | MX359825B (enExample) |
| MY (1) | MY172422A (enExample) |
| PE (1) | PE20142343A1 (enExample) |
| PH (1) | PH12014500444A1 (enExample) |
| PL (1) | PL3199533T3 (enExample) |
| RS (1) | RS58870B1 (enExample) |
| RU (1) | RU2617678C2 (enExample) |
| SG (1) | SG11201400244YA (enExample) |
| SI (1) | SI3199533T1 (enExample) |
| SM (1) | SMT201900292T1 (enExample) |
| TW (1) | TWI549949B (enExample) |
| WO (1) | WO2013031922A1 (enExample) |
| ZA (1) | ZA201401071B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| PL2848254T3 (pl) | 2012-05-07 | 2017-03-31 | Kissei Pharmaceutical Co., Ltd. | Pochodne pirazolu i ich zastosowanie w celach medycznych |
| US9783543B2 (en) | 2012-11-19 | 2017-10-10 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines |
| MX346453B (es) * | 2013-02-04 | 2017-03-17 | Taisho Pharmaceutical Co Ltd | Medicamento profilactico o terapeutico para el estreñimiento. |
| WO2014182955A2 (en) * | 2013-05-08 | 2014-11-13 | The University Of Houston System | Targeting the egfr-sglt1 interaction for cancer therapy |
| CN105294703B (zh) * | 2015-10-23 | 2018-01-23 | 西安近代化学研究所 | 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法 |
| JP2019526547A (ja) | 2016-08-11 | 2019-09-19 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 置換されているピラゾリニル誘導体、それらを製造する方法、並びに、除草剤及び／又は植物成長調節剤としてのそれらの使用 |
| KR102467045B1 (ko) | 2016-08-15 | 2022-11-11 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 3-아미노-1-(2,6-이치환 페닐)피라졸의 제조 방법 |
| TWI805699B (zh) | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| MX2020010433A (es) * | 2018-04-04 | 2020-10-28 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos. |
| AU2020341926B2 (en) * | 2019-09-04 | 2026-02-26 | Shionogi & Co., Ltd. | Therapeutic or prophylactic method for diabetes using combination medicine |
| US20230210831A1 (en) * | 2019-09-04 | 2023-07-06 | Japan Tobacco Inc. | Chronic kidney disease treatment or prevention method |
| CN115209919B (zh) * | 2020-03-19 | 2024-12-31 | 日本烟草产业株式会社 | 慢性心衰的治疗或预防方法 |
| WO2025249555A1 (en) * | 2024-05-31 | 2025-12-04 | Japan Tobacco Inc. | Method for treating or preventing hypertrophic cardiomyopathy |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| GEP20053476B (en) * | 1999-08-12 | 2005-03-25 | Upjohn Co | 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents |
| US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| BRPI0313290B1 (pt) * | 2002-08-08 | 2016-12-06 | Kissei Pharmaceutical | derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal |
| JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| DE102004028241B4 (de) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| MX2007005137A (es) | 2004-11-23 | 2007-06-22 | Warner Lambert Co | Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia. |
| WO2007034279A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| JP5069894B2 (ja) * | 2005-10-21 | 2012-11-07 | 田辺三菱製薬株式会社 | ピラゾール化合物 |
| TWI378922B (en) * | 2005-10-21 | 2012-12-11 | Mitsubishi Tanabe Pharma Corp | A pyrazole compound |
| EP1951678A1 (en) | 2005-10-21 | 2008-08-06 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
| US20070117858A1 (en) | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
| EP2079728B1 (en) * | 2006-10-10 | 2013-09-25 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| JP4994295B2 (ja) * | 2007-04-20 | 2012-08-08 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP2010222298A (ja) * | 2009-03-24 | 2010-10-07 | Shionogi & Co Ltd | Ｎｐｙｙ５受容体拮抗作用を有するピロリドン誘導体 |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| EP2560966B1 (en) | 2010-03-30 | 2021-01-06 | Verseon International Corporation | Multisubstituted aromatic compounds as inhibitors of thrombin |
| JP5944823B2 (ja) | 2010-07-02 | 2016-07-05 | あすか製薬株式会社 | 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤 |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
-
2012
- 2012-08-28 AR ARP120103173A patent/AR087701A1/es active IP Right Grant
- 2012-08-30 TW TW101131507A patent/TWI549949B/zh active
- 2012-08-30 MY MYPI2014000387A patent/MY172422A/en unknown
- 2012-08-30 EP EP19159289.8A patent/EP3524599A1/en not_active Withdrawn
- 2012-08-30 RS RS20190581A patent/RS58870B1/sr unknown
- 2012-08-30 PE PE2014001489A patent/PE20142343A1/es active IP Right Grant
- 2012-08-30 SM SM20190292T patent/SMT201900292T1/it unknown
- 2012-08-30 DK DK17157922.0T patent/DK3199533T3/da active
- 2012-08-30 RU RU2014112048A patent/RU2617678C2/ru active
- 2012-08-30 WO PCT/JP2012/072066 patent/WO2013031922A1/ja not_active Ceased
- 2012-08-30 CN CN201280050398.9A patent/CN103917535B/zh active Active
- 2012-08-30 SG SG11201400244YA patent/SG11201400244YA/en unknown
- 2012-08-30 PH PH1/2014/500444A patent/PH12014500444A1/en unknown
- 2012-08-30 KR KR1020147004780A patent/KR101989203B1/ko active Active
- 2012-08-30 US US13/599,665 patent/US8846746B2/en active Active
- 2012-08-30 EP EP25203401.2A patent/EP4656638A3/en active Pending
- 2012-08-30 HK HK15102725.1A patent/HK1202290A1/en unknown
- 2012-08-30 MX MX2014002552A patent/MX359825B/es active IP Right Grant
- 2012-08-30 CA CA2845127A patent/CA2845127C/en active Active
- 2012-08-30 BR BR112014004651-4A patent/BR112014004651B1/pt active IP Right Grant
- 2012-08-30 JP JP2012190429A patent/JP6091811B2/ja active Active
- 2012-08-30 EP EP17157922.0A patent/EP3199533B1/en active Active
- 2012-08-30 AU AU2012302723A patent/AU2012302723B2/en active Active
- 2012-08-30 PL PL17157922T patent/PL3199533T3/pl unknown
- 2012-08-30 EP EP12827193.9A patent/EP2784074A4/en not_active Withdrawn
- 2012-08-30 SI SI201231595T patent/SI3199533T1/sl unknown
-
2014
- 2014-02-02 IL IL230763A patent/IL230763A/en active IP Right Grant
- 2014-02-11 ZA ZA2014/01071A patent/ZA201401071B/en unknown
- 2014-02-25 CO CO14038962A patent/CO6890098A2/es active IP Right Grant
- 2014-02-27 CL CL2014000490A patent/CL2014000490A1/es unknown
- 2014-07-29 US US14/445,500 patent/US20150183763A1/en not_active Abandoned
-
2017
- 2017-02-08 JP JP2017021326A patent/JP2017082005A/ja not_active Ceased
- 2017-12-21 US US15/850,874 patent/US20180346449A1/en not_active Abandoned
-
2018
- 2018-05-02 JP JP2018088578A patent/JP2018115216A/ja not_active Ceased
-
2019
- 2019-05-08 CY CY20191100491T patent/CY1121631T1/el unknown
- 2019-11-07 US US16/677,523 patent/US20200317644A1/en not_active Abandoned
-
2020
- 2020-05-01 JP JP2020081097A patent/JP2020125348A/ja not_active Ceased
-
2021
- 2021-09-06 AR ARP210102479A patent/AR123441A2/es unknown
-
2022
- 2022-12-02 US US18/061,309 patent/US20230348438A1/en active Pending
-
2023
- 2023-05-02 JP JP2023075967A patent/JP2023087032A/ja not_active Ceased
-
2025
- 2025-01-06 JP JP2025000092A patent/JP2025039641A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013063968A5 (enExample) | ||
| EA201391629A1 (ru) | Ингибиторы цсж-1r для лечения опухолей головного мозга | |
| JP2012144574A5 (enExample) | ||
| JP2013531029A5 (enExample) | ||
| RU2014112048A (ru) | Пиразольное соединение и его применение в фармацевтике | |
| MD20160078A2 (ro) | Inhibitori ai Syk | |
| EA201590020A1 (ru) | Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| MX2018010878A (es) | Compuestos de aril-monobactam biciclicos y metodos de uso de los mismos para el tratamiento de infecciones bacterianas. | |
| EA201590023A1 (ru) | Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
| JP2011513305A5 (enExample) | ||
| MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
| PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| UA115320C2 (uk) | Інгібітори кінази | |
| EA201100750A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| JP2013537203A5 (enExample) | ||
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| JP2015504081A5 (enExample) | ||
| WO2014128669A3 (en) | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
| EA201391558A1 (ru) | Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения | |
| EA201590021A1 (ru) | Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| JP2016537382A5 (enExample) | ||
| IN2014DN07283A (enExample) | ||
| EA201590022A1 (ru) | Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса |